The anti-asthmatics and copd drugs market size has grown steadily in recent years. It will grow from $85.08 billion in 2025 to $89.13 billion in 2026 at a compound annual growth rate (CAGR) of 4.8%. The growth in the historic period can be attributed to rising prevalence of asthma and copd, increasing smoking and air pollution levels, limited awareness about preventive therapies, availability of generic bronchodilators, growth in hospital pharmacy networks.
The anti-asthmatics and copd drugs market size is expected to see strong growth in the next few years. It will grow to $111.34 billion in 2030 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to advancements in biologics and monoclonal antibodies, integration of ai in treatment plans, increasing adoption of digital health solutions, expansion of online pharmacy channels, development of targeted therapies for severe copd. Major trends in the forecast period include personalized asthma management, telemedicine and remote patient monitoring, development of inhalable biologics, growing preference for combination therapies, focus on pediatric and geriatric formulations.
The rising prevalence of asthmatic disorders is expected to drive the growth of the anti-asthmatics and COPD drugs market. Asthma is a chronic condition characterized by airway inflammation and narrowing, which obstructs airflow to the lungs. The increasing incidence of asthma has prompted the development of novel anti-asthmatics and COPD therapies to manage symptoms and improve patient outcomes. For instance, in June 2025, according to the Official Statistics, a UK-based government department, emergency admissions for asthma in adults (19+) rose by 17% in the financial year ending 2024 compared to the previous year. Therefore, the growing number of asthmatic cases is encouraging innovation in respiratory therapies, driving market expansion.
Key companies in the market are investing in next-generation propellant inhalers to provide environmentally sustainable and patient-friendly drug delivery. These inhalers replace traditional hydrofluoroalkane (HFA) propellants with near-zero Global Warming Potential (GWP) alternatives while maintaining delivery efficiency. In May 2025, AstraZeneca plc, a UK-based biopharmaceutical company, launched Trixeo Aerosphere, a fixed-dose triple-combination COPD therapy (budesonide, glycopyrronium, and formoterol fumarate) delivered via a next-generation propellant. The inhaler achieves bioequivalence to prior formulations and reduces GWP by 99.9%, supporting sustainable healthcare without compromising efficacy.
In February 2024, GSK plc, a UK-based biopharmaceutical company, acquired Aiolos Bio for $1 billion. The acquisition, including Aiolos’s AIO-001 therapy, strengthens GSK’s respiratory portfolio by addressing severe asthma patients with low T2 inflammation, enhancing market reach and leadership. Aiolos Bio is a US-based biotechnology company specializing in treatments for respiratory and inflammatory diseases.
Major companies operating in the anti-asthmatics and copd drugs market are GlaxoSmithKline plc, AstraZeneca plc, Boehringer Ingelheim GmbH, Novartis AG, Sanofi S.A., Chiesi Farmaceutici S.p.A., Teva Pharmaceutical Industries Limited, Cipla Limited, Aurobindo Pharma Limited, KYORIN Holdings Inc., Nichi-Iko Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Daewoong Pharmaceutical Co. Ltd, Lupin Limited, Abbott Laboratories, Pfizer, Vectura Group, Bayer, Apotex Inc., EMS Pharma, Hypermarcas, Ache, Eurofarma, Biolab Farmaceuticad, Cristalia, Libbs, Julphar, Neopharma, Adcock Ingram, Aspen Nigeria.
North America was the largest region in the anti-asthmatics and COPD drugs market in 2025. Middle East is expected to be the fastest-growing region in the global anti-asthmatics and COPD drugs market during the forecast period. The regions covered in the anti-asthmatics and copd drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the anti-asthmatics and copd drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have affected the anti-asthmatics and copd drugs market by increasing the cost of imported active pharmaceutical ingredients (apis) and inhaler devices, which has disrupted supply chains in regions like asia-pacific and europe. The bronchodilator and combination drug segments are most impacted due to reliance on specialized components and inhaler technology. While tariffs have increased production costs, they also incentivize local manufacturing and innovation in cost-effective drug delivery systems, potentially boosting domestic production capabilities in some regions.
The anti-asthmatics and copd drugs market research report is one of a series of new reports that provides anti-asthmatics and copd drugs market statistics, including anti-asthmatics and copd drugs industry global market size, regional shares, competitors with a anti-asthmatics and copd drugs market share, detailed anti-asthmatics and copd drugs market segments, market trends and opportunities, and any further data you may need to thrive in the anti-asthmatics and copd drugs industry. This anti-asthmatics and copd drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Anti-asthmatic and chronic obstructive pulmonary disease (COPD) drugs are medications used to reduce the frequency of acute asthma attacks, emphysema, chronic bronchitis, and nighttime awakenings.
The main drug classes for anti-asthmatics and COPD include bronchodilators, anti-inflammatory drugs, monoclonal antibodies, and combination drugs. Bronchodilators, also known as bronchiolitis agents, relax the bronchi and bronchioles, reducing airway resistance and improving airflow. Drug types include antihistamines, long-acting β2-agonists (LABAs), inhaled corticosteroids, short-acting muscarinic receptor antagonists (SAMAs), and other anti-asthmatic and COPD drugs, including combination therapies. End users include patients with asthma and COPD, and these drugs are distributed through hospital pharmacies, private clinics, drug stores, retail pharmacies, and e-commerce platforms.
The anti-asthmatic and chronic obstructive pulmonary disease market consists of corticosteroid, bronchodilator, fluticasone and salmeterol. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The anti-asthmatics and copd drugs market size is expected to see strong growth in the next few years. It will grow to $111.34 billion in 2030 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to advancements in biologics and monoclonal antibodies, integration of ai in treatment plans, increasing adoption of digital health solutions, expansion of online pharmacy channels, development of targeted therapies for severe copd. Major trends in the forecast period include personalized asthma management, telemedicine and remote patient monitoring, development of inhalable biologics, growing preference for combination therapies, focus on pediatric and geriatric formulations.
The rising prevalence of asthmatic disorders is expected to drive the growth of the anti-asthmatics and COPD drugs market. Asthma is a chronic condition characterized by airway inflammation and narrowing, which obstructs airflow to the lungs. The increasing incidence of asthma has prompted the development of novel anti-asthmatics and COPD therapies to manage symptoms and improve patient outcomes. For instance, in June 2025, according to the Official Statistics, a UK-based government department, emergency admissions for asthma in adults (19+) rose by 17% in the financial year ending 2024 compared to the previous year. Therefore, the growing number of asthmatic cases is encouraging innovation in respiratory therapies, driving market expansion.
Key companies in the market are investing in next-generation propellant inhalers to provide environmentally sustainable and patient-friendly drug delivery. These inhalers replace traditional hydrofluoroalkane (HFA) propellants with near-zero Global Warming Potential (GWP) alternatives while maintaining delivery efficiency. In May 2025, AstraZeneca plc, a UK-based biopharmaceutical company, launched Trixeo Aerosphere, a fixed-dose triple-combination COPD therapy (budesonide, glycopyrronium, and formoterol fumarate) delivered via a next-generation propellant. The inhaler achieves bioequivalence to prior formulations and reduces GWP by 99.9%, supporting sustainable healthcare without compromising efficacy.
In February 2024, GSK plc, a UK-based biopharmaceutical company, acquired Aiolos Bio for $1 billion. The acquisition, including Aiolos’s AIO-001 therapy, strengthens GSK’s respiratory portfolio by addressing severe asthma patients with low T2 inflammation, enhancing market reach and leadership. Aiolos Bio is a US-based biotechnology company specializing in treatments for respiratory and inflammatory diseases.
Major companies operating in the anti-asthmatics and copd drugs market are GlaxoSmithKline plc, AstraZeneca plc, Boehringer Ingelheim GmbH, Novartis AG, Sanofi S.A., Chiesi Farmaceutici S.p.A., Teva Pharmaceutical Industries Limited, Cipla Limited, Aurobindo Pharma Limited, KYORIN Holdings Inc., Nichi-Iko Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Daewoong Pharmaceutical Co. Ltd, Lupin Limited, Abbott Laboratories, Pfizer, Vectura Group, Bayer, Apotex Inc., EMS Pharma, Hypermarcas, Ache, Eurofarma, Biolab Farmaceuticad, Cristalia, Libbs, Julphar, Neopharma, Adcock Ingram, Aspen Nigeria.
North America was the largest region in the anti-asthmatics and COPD drugs market in 2025. Middle East is expected to be the fastest-growing region in the global anti-asthmatics and COPD drugs market during the forecast period. The regions covered in the anti-asthmatics and copd drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the anti-asthmatics and copd drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have affected the anti-asthmatics and copd drugs market by increasing the cost of imported active pharmaceutical ingredients (apis) and inhaler devices, which has disrupted supply chains in regions like asia-pacific and europe. The bronchodilator and combination drug segments are most impacted due to reliance on specialized components and inhaler technology. While tariffs have increased production costs, they also incentivize local manufacturing and innovation in cost-effective drug delivery systems, potentially boosting domestic production capabilities in some regions.
The anti-asthmatics and copd drugs market research report is one of a series of new reports that provides anti-asthmatics and copd drugs market statistics, including anti-asthmatics and copd drugs industry global market size, regional shares, competitors with a anti-asthmatics and copd drugs market share, detailed anti-asthmatics and copd drugs market segments, market trends and opportunities, and any further data you may need to thrive in the anti-asthmatics and copd drugs industry. This anti-asthmatics and copd drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Anti-asthmatic and chronic obstructive pulmonary disease (COPD) drugs are medications used to reduce the frequency of acute asthma attacks, emphysema, chronic bronchitis, and nighttime awakenings.
The main drug classes for anti-asthmatics and COPD include bronchodilators, anti-inflammatory drugs, monoclonal antibodies, and combination drugs. Bronchodilators, also known as bronchiolitis agents, relax the bronchi and bronchioles, reducing airway resistance and improving airflow. Drug types include antihistamines, long-acting β2-agonists (LABAs), inhaled corticosteroids, short-acting muscarinic receptor antagonists (SAMAs), and other anti-asthmatic and COPD drugs, including combination therapies. End users include patients with asthma and COPD, and these drugs are distributed through hospital pharmacies, private clinics, drug stores, retail pharmacies, and e-commerce platforms.
The anti-asthmatic and chronic obstructive pulmonary disease market consists of corticosteroid, bronchodilator, fluticasone and salmeterol. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Anti-Asthmatics and COPD Drugs Market Characteristics
3. Anti-Asthmatics and COPD Drugs Market Supply Chain Analysis
4. Global Anti-Asthmatics and COPD Drugs Market Trends and Strategies
5. Anti-Asthmatics and COPD Drugs Market Analysis of End Use Industries
7. Global Anti-Asthmatics and COPD Drugs Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Anti-Asthmatics and COPD Drugs Total Addressable Market (TAM) Analysis for the Market
9. Anti-Asthmatics and COPD Drugs Market Segmentation
10. Anti-Asthmatics and COPD Drugs Market Regional and Country Analysis
11. Asia-Pacific Anti-Asthmatics and COPD Drugs Market
12. China Anti-Asthmatics and COPD Drugs Market
13. India Anti-Asthmatics and COPD Drugs Market
14. Japan Anti-Asthmatics and COPD Drugs Market
15. Australia Anti-Asthmatics and COPD Drugs Market
16. Indonesia Anti-Asthmatics and COPD Drugs Market
17. South Korea Anti-Asthmatics and COPD Drugs Market
18. Taiwan Anti-Asthmatics and COPD Drugs Market
19. South East Asia Anti-Asthmatics and COPD Drugs Market
20. Western Europe Anti-Asthmatics and COPD Drugs Market
21. UK Anti-Asthmatics and COPD Drugs Market
22. Germany Anti-Asthmatics and COPD Drugs Market
23. France Anti-Asthmatics and COPD Drugs Market
24. Italy Anti-Asthmatics and COPD Drugs Market
25. Spain Anti-Asthmatics and COPD Drugs Market
26. Eastern Europe Anti-Asthmatics and COPD Drugs Market
27. Russia Anti-Asthmatics and COPD Drugs Market
28. North America Anti-Asthmatics and COPD Drugs Market
29. USA Anti-Asthmatics and COPD Drugs Market
30. Canada Anti-Asthmatics and COPD Drugs Market
31. South America Anti-Asthmatics and COPD Drugs Market
32. Brazil Anti-Asthmatics and COPD Drugs Market
33. Middle East Anti-Asthmatics and COPD Drugs Market
34. Africa Anti-Asthmatics and COPD Drugs Market
36. Anti-Asthmatics and COPD Drugs Market Competitive Landscape and Company Profiles
37. Anti-Asthmatics and COPD Drugs Market Other Major and Innovative Companies
40. Anti-Asthmatics and COPD Drugs Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Anti-Asthmatics And COPD Drugs Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses anti-asthmatics and copd drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for anti-asthmatics and copd drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The anti-asthmatics and copd drugs market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Drug Class: Bronchodilators; Anti-Inflammatory Drugs; Monoclonal Antibodies; Combination Drugs2) By Distribution Channel: Hospital Pharmacies; General Pharmacies; Online Retailers
3) By End User: Asthma Patients; COPD Patients
4) By Therapy: Preventive; Curative
5) By Route Of Administration: Oral; Inhaled; Intravenous; Subcutaneous
6) By Age Group: Below 5; 5-14; 15-60; Above 60
Subsegments:
1) By Bronchodilators: Short-Acting Beta-Agonists (SABAs); Long-Acting Beta-Agonists (LABAs); Anticholinergics (Short-Acting And Long-Acting); Methylxanthines2) By Anti-Inflammatory Drugs: Corticosteroids (Inhaled And Systemic); Leukotriene Modifiers; Phosphodiesterase-4 Inhibitors
3) By Monoclonal Antibodies: Anti-IgE Antibodies; Anti-IL-5 Antibodies; Anti-IL-4 Or IL-13 Antibodies
4) By Combination Drugs: Combination Bronchodilator Inhalers (LABA + LAMA); Inhaled Corticosteroid + Long-Acting Beta-Agonist (ICS + LABA)
Companies Mentioned: GlaxoSmithKline plc; AstraZeneca plc; Boehringer Ingelheim GmbH; Novartis AG; Sanofi S.A.; Chiesi Farmaceutici S.p.A.; Teva Pharmaceutical Industries Limited; Cipla Limited; Aurobindo Pharma Limited; KYORIN Holdings Inc.; Nichi-Iko Pharmaceutical Co. Ltd.; Otsuka Pharmaceutical Co. Ltd.; Daewoong Pharmaceutical Co. Ltd; Lupin Limited; Abbott Laboratories; Pfizer; Vectura Group; Bayer; Apotex Inc.; EMS Pharma; Hypermarcas; Ache; Eurofarma; Biolab Farmaceuticad; Cristalia; Libbs; Julphar; Neopharma; Adcock Ingram; Aspen Nigeria.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Anti-Asthmatics and COPD Drugs market report include:- GlaxoSmithKline plc
- AstraZeneca plc
- Boehringer Ingelheim GmbH
- Novartis AG
- Sanofi S.A.
- Chiesi Farmaceutici S.p.A.
- Teva Pharmaceutical Industries Limited
- Cipla Limited
- Aurobindo Pharma Limited
- KYORIN Holdings Inc.
- Nichi-Iko Pharmaceutical Co. Ltd.
- Otsuka Pharmaceutical Co. Ltd.
- Daewoong Pharmaceutical Co. Ltd
- Lupin Limited
- Abbott Laboratories
- Pfizer
- Vectura Group
- Bayer
- Apotex Inc.
- EMS Pharma
- Hypermarcas
- Ache
- Eurofarma
- Biolab Farmaceuticad
- Cristalia
- Libbs
- Julphar
- Neopharma
- Adcock Ingram
- Aspen Nigeria.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 89.13 Billion |
| Forecasted Market Value ( USD | $ 111.34 Billion |
| Compound Annual Growth Rate | 5.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 31 |
